Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Heilongjiang Longde Pharmaceutical is a core manufacturing subsidiary of Harbin Pharmaceutical Group (Hayao), one of China's largest pharmaceutical conglomerates. Based in Harbin, the company specializes in the large-scale production of chemical generics and traditional Chinese medicine (TCM) preparations. Its extensive product portfolio includes various dosage forms such as small and large volume injections, tablets, and capsules, targeting therapeutic areas like anti-infectives, cardiovascular health, and nutritional supplements. The company operates modern, GMP-certified facilities that serve as a critical production hub for its parent organization, playing a significant role in the domestic Chinese healthcare supply chain.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Heilongjiang Longde Pharmaceutical.